Fortschritte in der Kardiologie^[*]

Prof. Dr. med. Erland Erdmann war seit jeher ein kritischer Geist. Er hat die kritische, wissenschaftliche Kardiologie genauso stark gefördert und fördert sie immer noch, wie er eine Verschreibung von homöopathischen Substanzen wie Anus bovis ablehnte. Mit transparenten preußischen Tugenden motivierte er seine Schüler, ihren Beitrag in der Patientenversorgung und Forschung zu leisten. Der folgende Artikel beleuchtet ausgewählte Gebiete der Kardiologie, die durch Erland Erdmann entscheidend mitentwickelt wurden.

Schlüsselwörter

Herzinsuffizienz - koronare Herzerkrankung - perkutane Intervention

Key words

congestive heart failure - coronary artery disease - percutaneous intervention

^* Gewidmet Herrn Professor Dr. med. Erland Erdmann anlässlich seiner Verabschiedung als DMW-Herausgeber.

• Literatur

• 1 Baumgartner H, Falk V, Bax JJ. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Europ Heart j 2017; 38: 2739-2791
• 2 Bohm M, Beuckelmann D, Brown L. et al. Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Europ Heart jJ 1988; 9: 844-852
• 3 Bohm M, Gierschik P, Jakobs KH. et al. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation 1990; 82: 1249-1265
• 4 Bohm M, Morano I, Pieske B. et al. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan innthe failing human myocardium. Circulation Res 1991; 68: 689-701
• 5 Bohm M, Pieske B, Ungerer M. et al. Characterization of A1 adenosine receptors in atrial and ventricular myocardium from diseased human hearts. Circulation research 1989; 65: 1201-1211
• 6 Desai AS, McMurray JJ, Packer M. et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Europ Heart J 2015; 36: 1990-1997
• 7 Erdmann E, Hofling B. [Percutaneous transfemoral valvuloplasty of calcified and non-calcified aortic valves]. Dtsch Med Wochenschr 1987; 112: 1067-1072
• 8 Erdmann E, Krawietz W, Philipp G. et al. Purified cardiac cell membranes with high (Na+ + K+)ATPase activity contain significant NADH-vanadate reductase activity. Nature 1979; 282: 335-336
• 9 Erdmann E, Krawietz W, Phillipp G. et al. Stimulatory effect of vanadate on (Na+ + K+)-ATPase activity and on 3H-ouabain-binding in a cat heart cell membrane preparation. Nature 1979; 278: 459-461
• 10 Erdmann E, Schoner W. Ouabain-receptor interactions in (Na+ + K+)-ATPase preparations. 3. On the stability of the ouabain receptor against physical treatment, hydrolases and SH reagents. Biochim Biophy Acta 1973; 330: 316-324
• 11 Group CTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435
• 12 Hjalmarson A, Goldstein S, Fagerberg B. et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283: 1295-1302
• 13 McMurray JJ, Packer M, Desai AS. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New Engl J Med 2014; 371: 993-1004
• 14 Pitt B, Zannad F, Remme WJ. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med 1999; 341: 709-717
• 15 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Europ Heart J 2016; 37: 2129-2200
• 16 Roberts E, Ludman AJ, Dworzynski K. et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015; 350: h910
• 17 Schwinger RH, Bohm M, Koch A. et al. The failing human heart is unable to use the Frank-Starling mechanism. Circulation Res 1994; 74: 959-969
• 18 Schwinger RH, Bohm M, Muller-Ehmsen J. et al. Effect of inotropic stimulation on the negative force-frequency relationship in the failing human heart. Circulation 1993; 88: 2267-2276
• 19 Swedberg K, Komajda M, Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885
• 20 Ungerer M, Parruti G, Bohm M. et al. Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. Circulation Res 1994; 74: 206-213
• 21 von Scheidt W, Bohm M, Schneider B. et al. Isolated presynaptic inotropic beta-adrenergic supersensitivity of the transplanted denervated human heart in vivo. Circulation 1992; 85: 1056-1063